In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
The antimicrobial effects of T9 (3-(4-cinamyl-1-piperazinyl)iminomethyl rifamycin SV) alone and in combination with ofloxacin, against strains of M. leprae were evaluated, using an in vitro cell-free culture system. The minimum inhibitory concentrations (MICs) of T9 against rifampin-sensitive and rifampin-resistant strains of M. leprae were 0.1 microgram/ml and 0.4 microgram/ml, respectively. Furthermore, in common with rifabutin, but not with rifamycin, T9 demonstrated synergy with ofloxacin against both rifampin-sensitive rifampin-resistant strains of M. leprae. The results suggest that T9, in combination with ofloxacin as part of multidrug regimens, warrants further evaluation as treatment for patients with leprosy.
Dhople
A M
AM
Florida Institute of Technology, Melbourne, USA.
Dimova
V
V
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D001135:Armadillos / Q000382:microbiology; D004347:Drug Interactions; D007917:Leprostatic Agents / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000254:growth & development; D015242:Ofloxacin / Q000494:pharmacology; D017828:Rifabutin / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007917:Leprostatic Agents; D012294:Rifamycins; D017828:Rifabutin; D015242:Ofloxacin; D012293:Rifampin